) received some encouraging news with the European Commission
(EC) approving its candidate, Lemtrada, for adults suffering from
relapsing remitting multiple sclerosis (RRMS).
The approval did not come as a surprise as the European Medicines
Agency's Committee for Medicinal Products for Human Use had
recommended the approval of Lemtrada in Jun 2013.
The CHMP issued a positive opinion on Lemtrada based on two
pivotal phase III trials, which were completed in 2011. In the
first study, CARE-MS I, Lemtrada met the first primary endpoint.
Results showed that treatment with two annual cycles of Lemtrada
as compared to Rebif resulted in a 55% reduction in the relapse
rate over the two-year span of the study.
In the second study, CARE-MS II, Lemtrada met both the primary
endpoints. Results showed that treatment with Lemtrada resulted
in a 49% reduction in the relapse rate compared to Rebif, over a
two-year period. Additionally, Lemtrada showed a 42%
reduction in the risk of sustained accumulation (worsening) of
We remind investors that Lemtrada is under review for the above
mentioned indication in the U.S. The U.S. Food and Drug
Administration (FDA) is expected to render a decision on
Lemtrada's marketing application towards the end of this year.
We note that Lemtrada is the second RRMS drug from Sanofi to
receive EC approval in the last few weeks. On Aug 30, 2013, the
EC approved Aubagio as a once-daily treatment for adults
suffering from RRMS.
Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned
about generic erosion confronting most of Sanofi's key drugs.
Additionally, recent pipeline failures (oncology candidate -
iniparib and anticoagulant - otamixaban) have put immense
pressure on Sanofi's pipeline.
Not all large-cap pharma companies are performing as badly as
) are well placed with a Zacks Rank #2 (Buy).
BAYER A G -ADR (BAYRY): Free Stock Analysis
NOVO-NORDISK AS (NVO): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.